- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01316120
Randomized Comparison of Vaginal Self Sampling for Human Papillomavirus (HPV) Testing by Standard Versus Dry Vaginal Swabs (HPVDry)
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
High-risk human papillomavirus (HR-HPV) infections in women are clinically important because they have been associated with nearly all cases of preinvasive and invasive cervical neoplasia1. Genital HR-HPV related infection is common, affecting approximately 10-25% of women, depending on the population and age-groups studied2-4.
With the advance in our understanding of HPV biology and the development of technologies for HPV detection together with the poor sensitivity of a single Pap test, there has been now a growing interest concerning the potential use of HPV DNA testing as a screening tool for cervical cancer5.
Currently, there is no consensus on which sampling method is the most effective for HPV DNA testing. These last years, studies have reported that samples provided by women themselves were suitable for DNA testing and support the feasibility of self-collection for HPV DNA testing6-8. Data from these studies support that it is acceptable for the women and demonstrated that a fairly high concordance rate between the self- and physicians testing method has been achieved.
Potential advantage of self-collection is that it could improve access to health care, reduce healthcare costs and save time for patients and providers. Available data have been reported with the use of specimen transport medium (STM), but the use of dry vaginal swab may potentially offer similar reliability than standard STM. Small studies suggest that HPV test (PCR) sampled by physicians using dry vaginal swab seems to be as accurate as those performed in a standard medium for HPV detection9,10. Dry vaginal swab offers potential advantages in terms of being more convenient for collection and is less expensive than a vaginal swab placed in a transport medium.
The aim of our study is to assess the performance of self-obtained v-DRY versus "standard" v-STM and its acceptability.
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- 20 years or older,
- First consultation in our colposcopy unit,
- Understands study procedures and accepts voluntarily to participate by signing the informed consent form (ICF).
Exclusion Criteria:
- Previous hysterectomy,
- Pregnant,
- Virgin,
- Not able to comply with the protocol study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Diagnostický
- Přidělení: Randomizované
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: HPV Dry first
Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the "first" test.
All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests
|
Instructions will be given to the patients by a research nurse and ICF will be obtained.
For specimen collection, participants will be instructed to wash their hands before the procedure.
Each participant will receive a package containing a specimen collection kit.
Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
|
|
Experimentální: HPV standard transport medium
Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the "first" test.
All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests
|
Instructions will be given to the patients by a research nurse and ICF will be obtained.
For specimen collection, participants will be instructed to wash their hands before the procedure.
Each participant will receive a package containing a specimen collection kit.
Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
To assess sensibility and specificity of dry swabs for HPV diagnosis
Časové okno: day 1
|
Agreement between collection methods in terms of HPV risk categories will be measured using the kappa statistic ( ) with a precision of 10% (95% confidence interval).
This measure of agreement is 0 when the amount of agreement is what would be expected by chance and 1 when there is perfect agreement.
|
day 1
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Preference about HPV self-collection
Časové okno: day 1
|
Women will complete a self administered questionnaire on demographics and preference for sampling method (Dry versus standard)
|
day 1
|
|
Sensitivity and specificity of specimen transport medium (STM)
Časové okno: day 1
|
Sensitivity and specificity to detect high-risk HPV using v-STM as gold standard will be reported.
|
day 1
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Patrick Petignat, Prof, HUG
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- HPVDry
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .